Restamax Plc: FINNISH FINANCIAL SUPERVISORY AUTHORITY HAS

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 15, 2014 at 10:45 AM

Restamax Plc: FINNISH FINANCIAL SUPERVISORY AUTHORITY HAS APPROVED THE LISTING PROSPECTUS CONCERNING THE LISTING OF NEW SHARES ISSUED IN RESTAMAX PLC'S DIRECTED ISSUE

Restamax Plc STOCK EXCHANGE RELEASE 15 April 2014, 17:30 FINNISH FINANCIAL SUPERVISORY AUTHORITY HAS APPROVED THE LISTING PROSPECTUS CONCERNING THE LISTING OF NEW SHARES ISSUED IN RESTAMAX PLC'S DIRECTED ISSUE The Finnish Financial Supervisory Authority has today 15 April 2014 approved Restmax Plc's ('Restamax' or the 'Company') Finnish-language listing prospectus in accordance with the Finnish Securities Markets Act concerning the listing of the Company's 2,130,000 new shares on the official list of NASDAQ OMX Helsinki Ltd (the 'Helsinki Stock Exchange'). Restamax has on 4 March 2014 acquired all the shares in Rengasravintolat Oy. As part of the purchase price of the transaction, 2,130,000 new shares in Restamax were directed to the sellers of all the shares in Rengasravintolat Oy through a directed issue (the 'Listing Shares'). The transaction and the issue of the Listing Shares were announced on 5 March 2014. The Listing Shares were registered with the Trade Register maintained by the Finnish Patent and Registration Office on 11 March 2014. The Company has submitted a listing application to the Helsingin Stock Exchange for the admission of the Listing Shares to trading on the official list of the Helsinki Stock Exchange. The Finnish-language listing prospectus concerning the Listing Shares has been prepared only for listing, and no Listing Shares are offered or sold based on the Finnish-language listing prospectus. Trading in the Listing Shares is expected to commence on the official list of the Helsinki Stock Exchange on or about 17 April 2014. The Finnish-language listing prospectus approved by the Finnish Financial Supervisory Authority is available as of 15 April 2014 on Restamax's website at www.restamax.fi/sijoittajille. The listing prospectus has only been drafted in Finnish. The legal advisor to the Company is Castrén & Snellman Attorneys Ltd and the Company's auditor is Deloitte & Touche Oy. Restamax Plc Markku Virtanen CEO Additional information: CEO Markku Virtanen, Restamax Plc, +358 (0)400 836 477, markku.virtanen@restamax.fi Chairman of the Board Timo Laine, Restamax Plc, +358 (0)400 626 064, timo.laine@restamax.fi Restamax Plc is a Finnish restaurant business group established in 1996. The company has continued to grow steadily throughout its history. The group companies include approximately 80 restaurants, cafés, pubs and nightclubs all over Finland. Well-known restaurant concepts of the group include Ristorante Bella Roma, Gringos Locos, Viihdemaailma Ilona, Daddy's Diner and Stefan's Steakhouse. Wayne's Coffee is also a part of the company's portfolio. Restamax Plc employs approximately 900 people, the group's 2013 pro forma turnover was MEUR 87.0 and its EBITDA MEUR 13.3. www.restamax.fi. NOTICE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, SOUTH AFRICA, SINGAPORE OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. This release is not a prospectus, and thus, is not an offer for securities. No securities are offered based on this release in any jurisdiction. Securities are also not offered based on the Finnish-language prospectus approved by the Finnish Financial Supervisory Authority in any jurisdiction. Investors must make their investment decisions based only on the information presented in the Finnish-language prospectus approved by the Finnish Financial Supervisory Authority and other information published by the Company. Shares cannot be offered or sold in the United States without registration in accordance with the US Securities Act of 1933 (as amended) or in reliance on an exemption from the registration requirements of the US Securities Act of 1933. Restamax has not registered, and does not intend to register, any part of a possible offer in the United States, nor does it intend to offer securities to the public in the United States. The Company's shares are not, and will not be, registered in accordance with the securities market legislation of the United States, Canada, Australia, Hong Kong, South Africa, Singapore or Japan, nor will the Company's shares be offered or sold to or on behalf of or in favour of residents or citizens of the United States, Canada, Australia, Hong Kong, South Africa, Singapore or Japan. This release may include forward-looking statements. These forward-looking statements include factors that are not historical facts, statements on, among other things, Restamax's results, financial position, solvency, opportunities, growth, strategies and Restamax's intentions, beliefs and current expectations concerning its industry. By nature, forward-looking statements involve risks and uncertainties, because they relate to events or are due to circumstances that may or may not occur in the future and, thus, express only the circumstances at the time they are given. Restamax gives notice that forward-looking statements are no assurance of future performance, and that its actual results, financial position and solvency as well as the development of its industry could significantly differ from what has been stated or proposed in the forward- looking statements herein. In addition, even if Restamax's results, financial position and solvency as well as the development of its industry correspond to the forward-looking statements herein, such results or development are no indication of future results or developments. Restamax does not undertake to verify expectations or estimates or to publish corrections to forward-looking statements reflecting events or circumstances subsequent to the publication of this release. [HUG#1777546]

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Innovent's SINTBILO® Hits Primary Endpoint in Study

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

LG's ASIL D Certification: A Game Changer in Autos

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Fibocom LTE Modules Test Drive Satellite Connectivity

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Wuliangye Aims for Global Branding Boost at Panda Event

Wuliangye Takes Center Stage at Global Event Everyone's chasing that global branding magic, but here's Wuliangye strutting its stuff at the Global Panda Partners Conference. Held in Sichuan Province from November 2 to 4, this is not just another show; it's a bold move from the Chinese baijiu maker to push the 'harmony and coexistence' mantra on the world stage. Not just...

ASMAX Unleashes Next-Level Motorcycle Comms at EICMA

Transforming the Motorcycle Communication Landscape Motorcycling ain't just about the roaring engines and the rubber on the road. In the world of helmets and handlebars, some bright minds are weaving tech magic at the EICMA 2026 in Milan. ASMAX has rolled out its shiny new RoamX intercom gadget, leaving folks buzzing at Hall 6. What RoamX Brings to the Table This ain't...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...